Attralus is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, developing transformative medicines for patients with systemic amyloidosis. Its proprietary pan-amyloid removal (PAR) platform pairs a pan-amyloid binding peptide with a humanized IgG1 monoclonal antibody so the resulting fusion protein binds amyloid… - View it on GitHub